• Publications
  • Influence
Clinical Pharmacokinetics of Irinotecan
  • G. Chabot
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 1 October 1997
SummaryThis article reviews the clinical pharmacokinetics of a water-soluble analogue of camptothecin, irinotecan {CPT-11 or 7-ethyl-10-[4-(1-piperidmo)-1-piperidino]-carbonyloxy-camptothecin}.Expand
  • 208
  • 17
Retinoic acid metabolism and mechanism of action: a review.
Retinoids are vitamin A (retinol) derivatives essential for normal embryo development and epithelial differentiation. These compounds are also involved in chemoprevention and differentiation therapyExpand
  • 190
  • 15
Activation of Retinoic Acid Receptor-dependent Transcription by All-trans-retinoic Acid Metabolites and Isomers*
We have shown that four metabolites of all-trans-retinoic acid (ATRA) (4-oxo-, 4-OH-, 18-OH-, and 5,6-epoxy-RA) can induce maturation of NB4 promyelocytic leukemia cells (Idres, N., Benoit, G.,Expand
  • 136
  • 15
  • PDF
Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites.
Cytochrome P450 (P450)-dependent metabolism of all-trans-retinoic acid (atRA) is important for the expression of its biological activity. Because the human P450s involved in the formation of theExpand
  • 177
  • 9
  • PDF
Expression and inducibility of cytochrome P450 3A9 (CYP3A9) and other members of the CYP3A subfamily in rat liver.
Quantitative reverse-transcriptase polymerase chain reaction was used to determine the content of mRNA derived from four CYP3A genes (CYP3A2, CYP3A9, CYP3A18, and CYP3A23) in rat liver. CYP3A2 andExpand
  • 139
  • 8
Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
BACKGROUND Irinotecan (CPT-11) is a novel water-soluble camptothecin derivative selected for clinical testing based on its good in vitro and in vivo activity in various experimental systems,Expand
  • 163
  • 7
CPT-11-induced cholinergic effects in cancer patients.
  • 110
  • 6
Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
PURPOSE A phase I study was undertaken to determine the maximum-tolerated dose (MTD), principal toxicities, and pharmacokinetics of the novel topoisomerase I inhibitor irinotecan (CPT-11). PATIENTSExpand
  • 288
  • 5
Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.
In an attempt to better understand breast tumors sensitivity or resistance to anticancer drugs, the main drug-metabolizing enzyme systems were evaluated in both breast tumors and their correspondingExpand
  • 101
  • 5
Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids.
The purpose of this work was to identify the principal human cytochrome P450s (CYPs) involved in the metabolism of the retinoic acid (RA) isomers, 9-cis- and 13-cis-RA, by using a combination ofExpand
  • 77
  • 5
...
1
2
3
4
5
...